Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)(1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-kappaP)gold
-
24% inhibition at 0.02 mM
(4-chloro-2-trifluoromethyl-phenyl)-carbamic acid 5-methyl-2-oxo-1-[(4-oxo-pent-2-enylcarbamoyl)-methyl]-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-methyl ester
-
-
(5Z)-3-(2,4-difluorobenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-(3-methoxybenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-(4-fluorobenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-(4-methylbenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-benzyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-ethyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-methyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-[4-(trifluoromethyl)benzyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(S)-2-(1-(4-benzylpiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl)isoindoline-1,3-dione
-
-
(S)-2-(1-(4-benzylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)isoindoline-1,3-dione
-
-
(S)-2-(1-(4-benzylpiperidin-1-yl)-4-methyl-1-oxopentan-2-yl)isoindoline-1,3-dione
-
-
2,2'-((2S,2'S)-piperazine-1,4-diylbis(1-oxo-3-phenylpropane-2,1-diyl))bis(isoindoline-1,3-dione)
-
-
2,2'-((2S,2'S)-piperazine-1,4-diylbis(3-methyl-1-oxobutane-2,1-diyl))bis(isoindoline-1,3-dione)
-
-
2,2'-((2S,2'S)-piperazine-1,4-diylbis(4-methyl-1-oxopentane-2,1-diyl))bis(isoindoline-1,3-dione)
-
-
2,2'-((2S,2'S,3R,3'R)-piperazine-1,4-diylbis(3-methyl-1-oxopentane-2,1-diyl))bis(isoindoline-1,3-dione)
-
-
2-((2S,3S)-1-(4-benzylpiperidin-1-yl)-3-methyl-1-oxopentan-2-yl)isoindoline-1,3-dione
-
-
2-[(2S)-1-(morpholin-4-yl)-1-oxo-3-phenylpropan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-1-oxo-3-phenyl-1-(piperidin-1-yl)propan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-1-oxo-3-phenyl-1-(pyrrolidin-1-yl)propan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-3-methyl-1-(morpholin-4-yl)-1-oxobutan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-3-methyl-1-oxo-1-(piperidin-1-yl)butan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-3-methyl-1-oxo-1-(pyrrolidin-1-yl)butan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-4-methyl-1-(morpholin-4-yl)-1-oxopentan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-4-methyl-1-oxo-1-(piperidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S)-4-methyl-1-oxo-1-(pyrrolidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S,3R)-3-methyl-1-(morpholin-4-yl)-1-oxopentan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S,3R)-3-methyl-1-oxo-1-(piperidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[(2S,3R)-3-methyl-1-oxo-1-(pyrrolidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
-
-
2-[3-(isobutylamino-methyl)-2-oxo-5-phenyl-2,3-dihydrobenzo[e][1,4]diazepin-1-yl]-N-(4-oxo-pent-2-enyl)-acetamide
-
-
3,3'-(3,7,12,17-tetramethylporphyrin-2,18-diyl)dipropanoic acid
-
-
3-((2-chloro-6-methoxyquinolin-3-yl)methylene)-5-(2,4-dimethylphenyl)furan-2(3H)-one
IC50 value on parasite 0.50 microg/ml
3-((2-chloro-6-methoxyquinolin-3-yl)methylene)-5-(4-chlorophenyl)furan-2(3H)-one
IC50 value on parasite 0.61 micro/ml
3-(1-benzoyl-5-(4-flurophenyl)-4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-one
3-adamantyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-(2-chlorophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-(4-cyanophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-cyclohexylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-methylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenoxypiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,4-dichlorobenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,4-dimethoxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,5-ditrifluoromethylbenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2-bromobenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2-chlorobenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2-trifluoromethoxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3,4-difluorobenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-carboxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-fluorobenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-isopropylbenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-methoxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-methylbenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-trifluoromethoxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-chlorobenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-fluorobenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-methoxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-methylbenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-trifluoromethoxybenzylidene)1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-trifluoromethylbenzylidene)
-
-
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-benzylidene-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(4-pyridylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[2-oxo-2-(piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
3-[4-(benzylsulfamoyl)phenyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)propanamide
-
less than 5% inhibition at 0.01 mM
3-[4-[(2-phenylethyl)sulfamoyl]phenyl]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)propanamide
-
94.5% inhibition at 0.01 mM
3-[4-[(2-phenylethyl)sulfamoyl]phenyl]-N-(pyridin-2-ylmethyl)propanamide
-
10.7% inhibition at 0.01 mM
3-[4-[(2-phenylethyl)sulfamoyl]phenyl]-N-(thiophen-2-ylmethyl)propanamide
-
15.2% inhibition at 0.01 mM
3-[4-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)propanamide
-
32.7% inhibition at 0.01 mM
3-[4-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)propanamide
-
45.1% inhibition at 0.01 mM
amino[(2E)-2-[1-(4-methoxyphenyl)ethylidene]hydrazinyl]methanethiol
-
auranofin
-
30% inhibition at 0.02 mM
benzyl (1-[[(2S)-2-cyanopyrrolidin-1-yl]carbonyl]cyclohexyl)carbamate
-
benzyl [1-[(2-oxoethyl)carbamoyl]cyclohexyl]carbamate
-
benzyl [1-[(cyanomethyl)amino]-2-methyl-1-oxopropan-2-yl]carbamate
-
benzyl [1-[(cyanomethyl)carbamoyl]cyclohexyl]carbamate
-
chicken egg white cystatin
-
-
-
Chloroquine diphosphate
-
-
chloro[N-[1-(hydroxy-kappaO)-3-methylbutan-2-yl]pyridine-2-carboxamidato(2-)-kappa2N1,N2]aurate(2-)
-
43% inhibition at 0.02 mM
cisplatin
-
43% inhibition at 0.02 mM
deuteroporphyrin IX 2,4 (4,2) hydroxyvinyl
-
-
deuteroporphyrin IX 2-vinyl, 4-hydroxymethyl
-
-
dichloro[3-(propan-2-yl)-2-(pyridin-2-yl-kappaN)-4,5-dihydro-1,3-oxazol-3-ium-kappaN]aurate(1-) hexafluorophosphate
-
59% inhibition at 0.02 mM
heme
-
heme inhibits falcipain-2 activity against both human hemoglobin and chromogenic peptide substrates through a noncompetitive-like mechanism
isohematoporphyrin IX
-
-
mesoporphyrin IX dimethyl ester
-
-
methyl (2E)-4-[({(3R)-3-[({[4-chloro-2-(trifluoromethyl)phenyl]carbamoyl}oxy)methyl]-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1-yl}acetyl)amino]but-2-enoate
-
-
N-((S)-1-(((S)-1-(((S)-1-(2-((4-fluorophenoxy)methyl)-4,5-dihydro-1H-imidazol-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)piperidine-1-carboxamide
compound inhibits the growth of the drug resistant parasite Dd2. IC50 value for strain 3D/ 0.0055 mM
N-((S)-1-(((S)-1-(((S)-2-((S)-2-((4-fluorophenoxy)methyl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)morpholine-4-carboxamide
compound exhibits potent anti-parasitic activity and a 7- to 12fold higher potency against drug resistant Dd2 and MCamp isolates, than the laboratory strain 3D7. IC50 value for strain 3D7 0.0009 mM
N-(1,3-benzothiazol-2-yl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
-
41.5% inhibition at 0.01 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[4-[(2-phenylethyl)sulfamoyl]phenyl]acetamide
-
less than 5% inhibition at 0.01 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
-
23% inhibition at 0.01 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl]propanamide
-
6.3% inhibition at 0.01 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-[(3-methoxyphenyl)sulfamoyl]phenyl]propanamide
-
17.9% inhibition at 0.01 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(2-phenylethyl)sulfamoyl]benzamide
-
less than 5% inhibition at 0.01 mM
N-(3,4-dimethoxyphenyl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
-
15% inhibition at 0.01 mM
N-(3-hydroxy-4-methoxyphenyl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
-
13.6% inhibition at 0.01 mM
N-(4-oxo-pent-2-enyl)-2-(2-oxo-5-phenyl-3-morpholin-1-ylmethyl-2,3-dihydro-benzo[e][1,4]diazepin-1-yl)-acetamide
-
-
N-(4-oxo-pent-2-enyl)-2-(2-oxo-5-phenyl-3-piperidin-1-ylmethyl-2,3-dihydro-benzo[e][1,4] diazepin-1-yl)-acetamide
-
80% inhibition at 0.1 mM, no inhibition at 0.03 mM
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
-
46.5% inhibition at 0.01 mM
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-[4-[(4-fluorophenyl)sulfamoyl]phenyl]propanamide
-
72.9% inhibition at 0.01 mM
N-(cyanomethyl)-1-([[(1S,2S)-2-phenylcyclopropyl]carbonyl]amino)cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[(3-cyclopentylpropanoyl)amino]cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[(cyclopentylacetyl)amino]cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[[3-(2,3-dimethoxyphenyl)propanoyl]amino]cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[[3-(2-methoxyphenyl)propanoyl]amino]cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[[3-(4-methoxyphenyl)propanoyl]amino]cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[[3-(furan-2-yl)propanoyl]amino]cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[[3-(pyridin-3-yl)propanoyl]amino]cyclohexanecarboxamide
-
N-(cyanomethyl)-1-[[3-(thiophen-2-yl)propanoyl]amino]cyclohexanecarboxamide
-
N-methyl mesoporphyrin
-
-
N-methyl protoporphyrin IX
-
-
N-[(2S)-1-[(1-cyanocyclopropyl)amino]-1-oxo-3-(pyridin-3-yl)propan-2-yl]-3-(1H-imidazol-2-yl)benzamide
P2-modified aminonitrile based inhibitor, not cytotoxic to either cancer (HeLa) or normal (Huvec) human cell lines
N-[(2S)-1-[(1-cyanocyclopropyl)amino]-1-oxo-3-(pyridin-3-yl)propan-2-yl]-3-(1H-tetrazol-1-yl)benzamide
compound shows more than 500fold selectivity for falcipain-2 over cathepsin B, K and L and about 30fold selectivity over cathepsin S. Not cytotoxic to either cancer (HeLa) or normal (Huvec) human cell lines
potassium bis(1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)aurate(1-)
-
66% inhibition at 0.02 mM
RLLGAP-(cis-4-aminocyclohexane carboxylic acid)-QLVSGI
-
-
RLLGAP-(cis-4-aminocyclohexane carboxylic acid)-QLVSGI-betaAla-betaAla-PW
-
-
RLLGAP-gamma-aminobutyric acid-QLVSGI
-
-
RLLGAP-gamma-aminobutyric acid-QLVSGI-betaAla-betaAla-PW
-
-
RLLGAPV-(cis-4-aminocyclohexane carboxylic acid)-RQLVSGI
-
63% inhibition at 0.005 mM
RLLGAPV-(cis-4-aminocyclohexane carboxylic acid)-RQLVSGI-betaAla-betaAla-PW
-
-
RLLGAPV-gamma-aminobutyric acid-RQLVSGI
-
57% inhibition at 0.005 mM
RLLGAPV-gamma-aminobutyric acid-RQLVSGI-betaAla-betaAla-PW
-
-
SERPINB3
potent cross-class inhibitor of cysteine cathepsins L, K, S and papain, inhibits proteolytic activities as well as specific hemoglobinolytic activity of FP2 via noncovalent interaction. Disease state mutant serpin-Gly351Ala displays better anti-protease activity against FP2
-
[(3R)-2-oxo-1-(2-oxo-2-[[(2E)-4-oxopent-2-en-1-yl]amino]ethyl)-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]methyl [4-chloro-2-(trifluoromethyl)phenyl]carbamate
-
-
[(5Z)-2,4-dioxo-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidin-3-yl]acetic acid
-
-
[3-benzyl-2-(pyridin-2-yl-kappaN)-4,5-dihydro-1,3-oxazol-3-ium-kappaN](dichloro)aurate(1-) hexafluorophosphate
-
54% inhibition at 0.02 mM
3-(1-benzoyl-5-(4-flurophenyl)-4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-one
-
compound provides complete protection to the infected mice at 24 mg/kg for 4 days
3-(1-benzoyl-5-(4-flurophenyl)-4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-one
-
E-64
-
97.4% inhibition at 0.01 mM
additional information
-
not inhibited by pyrimethamine
-
additional information
density functional theory calculations of binding of different derivatives of acetophenone thiosemicarbazone and propiophenone thiosemicarbazone acting as inhibitors reveal covalent interaction between the thiocarbonyl carbon of the thiosemicarbazone moiety and the thiolate sulfur of the active site cysteine residue of falcipain-2. Acetophenone thiosemicarbazone and propiophenone thiosemicarbazone derivatives are potential reversible covalent inhibitors of falcipain-2
-
additional information
analysis of binding modes for 20 reversible peptide-based inhibitors and identification of near-native ligand conformations. The reversibility of the studied inhibitors, together with their predicted substrate-like orientation and the presence of a scissile peptide-bond at the P1 site, suggest a noncovalent substrate-like inhibition mechanism
-
additional information
-
analysis of binding modes for 20 reversible peptide-based inhibitors and identification of near-native ligand conformations. The reversibility of the studied inhibitors, together with their predicted substrate-like orientation and the presence of a scissile peptide-bond at the P1 site, suggest a noncovalent substrate-like inhibition mechanism
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Carcinoma, Hepatocellular
Synthesis, antimalarial activity in vitro, and docking studies of novel neolignan derivatives.
Chagas Disease
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
Fascioliasis
Antigenicity of a proteolytic enzyme of Fasciola hepatica.
Infections
Falcipain cysteine proteases of malaria parasites: An update.
Infections
Probing the aurone scaffold against Plasmodium falciparum: design, synthesis and antimalarial activity.
Malaria
A chimeric cysteine protease of Plasmodium berghei engineered to resemble the Plasmodium falciparum protease falcipain-2.
Malaria
A prodomain peptide of Plasmodium falciparum cysteine protease (falcipain-2) inhibits malaria parasite development.
Malaria
Analysis of non-peptidic compounds as potential malarial inhibitors against Plasmodial cysteine proteases via integrated virtual screening workflow.
Malaria
Antimalarial activities of novel synthetic cysteine protease inhibitors.
Malaria
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
Malaria
Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials.
Malaria
Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.
Malaria
Design, synthesis and biological evaluation of functionalized phthalimides: A new class of antimalarials and inhibitors of falcipain-2, a major hemoglobinase of malaria parasite.
Malaria
Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues.
Malaria
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain.
Malaria
Exploring the role of putative active site amino acids and pro-region motif of recombinant falcipain-2: a principal hemoglobinase of Plasmodium falciparum.
Malaria
Falcipain cysteine proteases of malaria parasites: An update.
Malaria
Falcipain cysteine proteases require bipartite motifs for trafficking to the Plasmodium falciparum food vacuole.
Malaria
Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series.
Malaria
Falcipain-2 inhibition by suramin and suramin analogues.
Malaria
Food vacuole targeting and trafficking of falcipain-2, an important cysteine protease of human malaria parasite Plasmodium falciparum.
Malaria
Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum.
Malaria
High-level expression of Falcipain-2 in Escherichia coli by codon optimization and auto-induction.
Malaria
Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors.
Malaria
In Silico Study Reveals How E64 Approaches, Binds to, and Inhibits Falcipain-2 of Plasmodium falciparum that Causes Malaria in Humans.
Malaria
Isolation and synthesis of falcitidin, a novel myxobacterial-derived acyltetrapeptide with activity against the malaria target falcipain-2.
Malaria
Novel series of 1,2,4-trioxane derivatives as antimalarial agents.
Malaria
Oxidation and Tyrosine Nitration Induce Structural Changes and Inhibits Plasmodium falciparum Falcipain-2 Activity In Vitro.
Malaria
Peptidomimetic nitrile inhibitors of malarial protease falcipain-2 with high selectivity against human cathepsins.
Malaria
Profiling the Structural Determinants of Heteroarylnitrile Scaffold-Based Derivatives as Falcipain-2 Inhibitors by In Silico Methods.
Malaria
Regulatory elements within the prodomain of Falcipain-2, a cysteine protease of the malaria parasite Plasmodium falciparum.
Malaria
Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease.
Malaria
Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones.
Malaria
Structure-function of falcipains: malarial cysteine proteases.
Malaria
Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity.
Malaria
Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.
Malaria
Synthesis and in vitro evaluation of gold(I) thiosemicarbazone complexes for antimalarial activity.
Malaria
Synthetic compounds from an in house library as inhibitors of falcipain-2 from Plasmodium falciparum.
Malaria
The impact of whole genome sequence data on drug discovery--a malaria case study.
Malaria
Toward the discovery of inhibitors of babesipain-1, a Babesia bigemina cysteine protease: in vitro evaluation, homology modeling and molecular docking studies.
Malaria, Falciparum
In Silico Study Reveals How E64 Approaches, Binds to, and Inhibits Falcipain-2 of Plasmodium falciparum that Causes Malaria in Humans.
Neoplasm Metastasis
In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2.
Osteoporosis
In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2.
Tuberculosis
Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.02908
(5Z)-3-(2,4-difluorobenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
(5Z)-3-(3-methoxybenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
(5Z)-3-(4-fluorobenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.04335
(5Z)-3-(4-methylbenzyl)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.03624
(5Z)-3-benzyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
(5Z)-3-ethyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
(5Z)-3-methyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
(5Z)-3-[4-(trifluoromethyl)benzyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.04784
(5Z)-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.01216
(S)-2-(1-(4-benzylpiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl)isoindoline-1,3-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.04824
(S)-2-(1-(4-benzylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)isoindoline-1,3-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.04423
(S)-2-(1-(4-benzylpiperidin-1-yl)-4-methyl-1-oxopentan-2-yl)isoindoline-1,3-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.0527
2,2'-((2S,2'S)-piperazine-1,4-diylbis(1-oxo-3-phenylpropane-2,1-diyl))bis(isoindoline-1,3-dione)
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.01689
2,2'-((2S,2'S)-piperazine-1,4-diylbis(3-methyl-1-oxobutane-2,1-diyl))bis(isoindoline-1,3-dione)
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.203
2,2'-((2S,2'S)-piperazine-1,4-diylbis(4-methyl-1-oxopentane-2,1-diyl))bis(isoindoline-1,3-dione)
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.00597
2,2'-((2S,2'S,3R,3'R)-piperazine-1,4-diylbis(3-methyl-1-oxopentane-2,1-diyl))bis(isoindoline-1,3-dione)
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.05379
2-((2S,3S)-1-(4-benzylpiperidin-1-yl)-3-methyl-1-oxopentan-2-yl)isoindoline-1,3-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.04943
2-[(2S)-1-(morpholin-4-yl)-1-oxo-3-phenylpropan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.03605
2-[(2S)-1-oxo-3-phenyl-1-(piperidin-1-yl)propan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.0876
2-[(2S)-1-oxo-3-phenyl-1-(pyrrolidin-1-yl)propan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.2056
2-[(2S)-3-methyl-1-(morpholin-4-yl)-1-oxobutan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.1305
2-[(2S)-3-methyl-1-oxo-1-(piperidin-1-yl)butan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.1416
2-[(2S)-3-methyl-1-oxo-1-(pyrrolidin-1-yl)butan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.1393
2-[(2S)-4-methyl-1-(morpholin-4-yl)-1-oxopentan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.2179
2-[(2S)-4-methyl-1-oxo-1-(piperidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.2362
2-[(2S)-4-methyl-1-oxo-1-(pyrrolidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.06057
2-[(2S,3R)-3-methyl-1-(morpholin-4-yl)-1-oxopentan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.1067
2-[(2S,3R)-3-methyl-1-oxo-1-(piperidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.1464
2-[(2S,3R)-3-methyl-1-oxo-1-(pyrrolidin-1-yl)pentan-2-yl]-1H-isoindole-1,3(2H)-dione
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.002
3,3'-(3,7,12,17-tetramethylporphyrin-2,18-diyl)dipropanoic acid
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.02908
3-adamantyl-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.01264
3-[2-oxo-2-(4-(2-chlorophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.01625
3-[2-oxo-2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.01123
3-[2-oxo-2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.01224
3-[2-oxo-2-(4-(4-cyanophenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-cyclohexylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-methylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.03375
3-[2-oxo-2-(4-phenoxypiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,4-dichlorobenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,4-dimethoxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.03528
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2,5-ditrifluoromethylbenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.02388
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2-bromobenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.0158
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2-chlorobenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.03528
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(2-trifluoromethoxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3,4-difluorobenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-carboxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.03325
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-fluorobenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.02389
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-isopropylbenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-methoxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.04533
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-methylbenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.04497
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(3-trifluoromethoxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-chlorobenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-fluorobenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-methoxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.04571
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-methylbenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.01344
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-trifluoromethoxybenzylidene)1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.01804
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-(4-trifluoromethylbenzylidene)
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.0388
3-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-5-benzylidene-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(4-pyridylpiperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.05
3-[2-oxo-2-(piperazin-1-yl)ethyl]-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
0.0027
3-[4-[(2-phenylethyl)sulfamoyl]phenyl]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)propanamide
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.0132
3-[4-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)propanamide
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.0098
3-[4-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)propanamide
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.000159
artemisinin
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.003
bilirubin
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.000066
Chloroquine diphosphate
Plasmodium falciparum
-
in 100 mM acetate buffer pH 5.5, at 37°C
0.0009
coproporphyrin
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.00048
deuteroporphyrin IX 2,4 (4,2) hydroxyvinyl
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.00062
deuteroporphyrin IX 2-vinyl, 4-hydroxymethyl
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.000515
heme
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.002
isohematoporphyrin IX
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.005
mesoporphyrin IX dimethyl ester
Plasmodium falciparum
-
IC50 above 0.005 mM, at pH 5.5 and 37°C
0.0089
N-(1,3-benzothiazol-2-yl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.0542
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.0081
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-[4-[(2-phenylethyl)sulfamoyl]phenyl]propanamide
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.007
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-[4-[(4-fluorophenyl)sulfamoyl]phenyl]propanamide
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.005
N-methyl mesoporphyrin
Plasmodium falciparum
-
IC50 above 0.005 mM, at pH 5.5 and 37°C
0.00037
N-methyl protoporphyrin IX
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.0000027
N-[(2S)-1-[(1-cyanocyclopropyl)amino]-1-oxo-3-(pyridin-3-yl)propan-2-yl]-3-(1H-imidazol-2-yl)benzamide
Plasmodium falciparum
pH not specified in the publication, temperature not specified in the publication
0.000003
N-[(2S)-1-[(1-cyanocyclopropyl)amino]-1-oxo-3-(pyridin-3-yl)propan-2-yl]-3-(1H-tetrazol-1-yl)benzamide
Plasmodium falciparum
pH not specified in the publication, temperature not specified in the publication
0.00055
protoporphyrin IX
Plasmodium falciparum
-
at pH 5.5 and 37°C
0.05
[(5Z)-2,4-dioxo-5-(2,4,6-trimethoxybenzylidene)-1,3-thiazolidin-3-yl]acetic acid
Plasmodium falciparum
-
IC50 above 0.05 mM, in 100 mM sodium acetate, pH 5.5, at 22°C
additional information
3-(1-benzoyl-5-(4-flurophenyl)-4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-one
0.000017
E-64
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, 10 mM dithiothreitol, at 22°C
0.000047
E-64
Plasmodium falciparum
-
in 100 mM sodium acetate, pH 5.5, at 22°C
additional information
3-(1-benzoyl-5-(4-flurophenyl)-4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-one
Plasmodium falciparum
IC50 value 0.0042 micro/ml, pH not specified in the publication, temperature not specified in the publication
additional information
3-(1-benzoyl-5-(4-flurophenyl)-4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-one
Plasmodium falciparum
-
IC50 value 0.0042 micro/ml, pH not specified in the publication, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Pandey, K.C.; Barkan, D.T.; Sali, A.; Rosenthal, P.J.
Regulatory elements within the prodomain of falcipain-2, a cysteine protease of the malaria parasite Plasmodium falciparum
PLoS ONE
4
e5694
2009
Plasmodium falciparum
brenda
Hansen, G.; Schwarzloh, B.; Rennenberg, A.; Heussler, V.T.; Hilgenfeld, R.
The macromolecular complex of ICP and falcipain-2 from Plasmodium: preparation, crystallization and preliminary X-ray diffraction analysis
Acta Crystallogr. Sect. F
67
1406-1410
2011
Plasmodium falciparum
brenda
Huang, H.; Lu, W.; Li, X.; Cong, X.; Ma, H.; Liu, X.; Zhang, Y.; Che, P.; Ma, R.; Li, H.; Shen, X.; Jiang, H.; Huang, J.; Zhu, J.
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent
Bioorg. Med. Chem. Lett.
22
958-962
2012
Plasmodium falciparum
brenda
Ettari, R.; Zappala, M.; Micale, N.; Grazioso, G.; Giofre, S.; Schirmeister, T.; Grasso, S.
Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors
Eur. J. Med. Chem.
46
2058-2065
2011
Plasmodium falciparum
brenda
Rizzi, L.; Sundararaman, S.; Cendic, K.; Vaiana, N.; Korde, R.; Sinha, D.; Mohmmed, A.; Malhotra, P.; Romeo, S.
Design and synthesis of protein-protein interaction mimics as Plasmodium falciparum cysteine protease, falcipain-2 inhibitors
Eur. J. Med. Chem.
46
2083-2090
2011
Plasmodium falciparum
brenda
Micale, N.; Cinellu, M.A.; Maiore, L.; Sannella, A.R.; Severini, C.; Schirmeister, T.; Gabbiani, C.; Messori, L.
Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro
J. Inorg. Biochem.
105
1576-1579
2011
Plasmodium falciparum
brenda
Ehmke, V.; Kilchmann, F.; Heindl, C.; Cui, K.; Huang, J.; Schirmeister, T.; Diederich, F.
Peptidomimetic nitriles as selective inhibitors for the malarial cysteine protease falcipain-2
MedChemComm
2
800-804
2011
Plasmodium falciparum (Q9N6S8)
-
brenda
Marques, A.F.; Gomes, P.S.; Oliveira, P.L.; Rosenthal, P.J.; Pascutti, P.G.; Lima, L.M.
Allosteric regulation of the Plasmodium falciparum cysteine protease falcipain-2 by heme
Arch. Biochem. Biophys.
573
92-99
2015
Plasmodium falciparum
brenda
Singh, A.K.; Rajendran, V.; Pant, A.; Ghosh, P.C.; Singh, N.; Latha, N.; Garg, S.; Pandey, K.C.; Singh, B.K.; Rathi, B.
Design, synthesis and biological evaluation of functionalized phthalimides: A new class of antimalarials and inhibitors of falcipain-2, a major hemoglobinase of malaria parasite
Bioorg. Med. Chem.
23
1817-1827
2015
Plasmodium falciparum
brenda
Sharma, R.K.; Younis, Y.; Mugumbate, G.; Njoroge, M.; Gut, J.; Rosenthal, P.J.; Chibale, K.
Synthesis and structure-activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2
Eur. J. Med. Chem.
90
507-518
2015
Plasmodium falciparum, Plasmodium falciparum W2
brenda
Omotuyi, I.O.; Hamada, T.
Dynamical footprint of falcipain-2 catalytic triad in hemoglobin-beta-bound state
J. Biomol. Struct. Dyn.
33
1027-1036
2015
Plasmodium falciparum
brenda
Grazioso, G.; Legnani, L.; Toma, L.; Ettari, R.; Micale, N.; De Micheli, C.
Mechanism of falcipain-2 inhibition by alpha,beta-unsaturated benzo[1,4]diazepin-2-one methyl ester
J. Comput. Aided Mol. Des.
26
1035-1043
2012
Plasmodium falciparum
brenda
Bertoldo, J.B.; Chiaradia-Delatorre, L.D.; Mascarello, A.; Leal, P.C.; Cordeiro, M.N.; Nunes, R.J.; Sarduy, E.S.; Rosenthal, P.J.; Terenzi, H.
Synthetic compounds from an in house library as inhibitors of falcipain-2 from Plasmodium falciparum
J. Enzyme Inhib. Med. Chem.
30
299-307
2015
Plasmodium falciparum
brenda
Cotrin, S.S.; Gouvea, I.E.; Melo, P.M.; Bagnaresi, P.; Assis, D.M.; Araujo, M.S.; Juliano, M.A.; Gazarini, M.L.; Rosenthal, P.J.; Juliano, L.; Carmona, A.K.
Substrate specificity studies of the cysteine peptidases falcipain-2 and falcipain-3 from Plasmodium falciparum and demonstration of their kininogenase activity
Mol. Biochem. Parasitol.
187
111-116
2013
Plasmodium falciparum
brenda
Alam, B.; Biswas, S.
Inhibition of Plasmodium falciparum cysteine protease falcipain-2 by a human cross-class inhibitor serpinB3 A mechanistic insight
Biochim. Biophys. Acta
1867
854-865
2019
Plasmodium falciparum (Q9N6S8), Plasmodium falciparum
brenda
Chakka, S.K.; Kalamuddin, M.; Sundararaman, S.; Wei, L.; Mundra, S.; Mahesh, R.; Malhotra, P.; Mohmmed, A.; Kotra, L.P.
Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents
Bioorg. Med. Chem.
23
2221-2240
2015
Plasmodium falciparum (Q9N6S8)
brenda
Nizi, E.; Sferrazza, A.; Fabbrini, D.; Nardi, V.; Andreini, M.; Graziani, R.; Gennari, N.; Bresciani, A.; Paonessa, G.; Harper, S.
Peptidomimetic nitrile inhibitors of malarial protease falcipain-2 with high selectivity against human cathepsins
Bioorg. Med. Chem. Lett.
28
1540-1544
2018
Plasmodium falciparum (Q9N6S8), Plasmodium falciparum
brenda
Himangini, Z.; Pathak, D.P.; Sharma, V.; Kumar, S.
Designing novel inhibitors against falcipain-2 of Plasmodium falciparum
Bioorg. Med. Chem. Lett.
28
1566-1569
2018
Plasmodium berghei, Plasmodium falciparum (Q9N6S8), Plasmodium falciparum
brenda
Akhter, M.; Saha, R.; Tanwar, O.; Mumtaz Alam, M.; Zaman, M.
Synthesis and antimalarial activity of quinoline-substituted furanone derivatives and their identification as selective falcipain-2 inhibitors
Med. Chem. Res.
24
879-890
2015
Plasmodium falciparum (Q9N6S8)
-
brenda
Ghogomu, J.; Nkungli, N.
DFT studies and topological analyses of electron density on acetophenone and propiophenone thiosemicarbazone derivatives as covalent inhibitors of falcipain-2, a major Plasmodium falciparum cysteine protease
Phys. Chem. Res.
5
795-817
2017
Plasmodium falciparum (Q9N6S8)
-
brenda
Hernandez Gonzalez, J.E.; Hernandez Alvarez, L.; Pascutti, P.G.; Valiente, P.A.
Predicting binding modes of reversible peptide-based inhibitors of falcipain-2 consistent with structure-activity relationships
Proteins
85
1666-1683
2017
Plasmodium falciparum (Q9N6S8), Plasmodium falciparum
brenda